Last reviewed · How we verify
GC3110A(Trivalent)
GC3110A(Trivalent) is a Therapeutic vaccine Biologic drug developed by Green Cross Corporation. It is currently in Phase 3 development. Also known as: GC3110A.
GC3110A is a trivalent vaccine designed to stimulate immune responses against multiple targets for therapeutic benefit.
GC3110A(Trivalent) is a small molecule vaccine used to study the safety and tolerability of a trivalent influenza vaccine. It is a supplement that is being investigated as a potential treatment for influenza.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | GC3110A(Trivalent) |
|---|---|
| Also known as | GC3110A |
| Sponsor | Green Cross Corporation |
| Drug class | Therapeutic vaccine |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
As a trivalent formulation, GC3110A likely combines three distinct antigenic components or epitopes to broaden immune coverage. The specific mechanism depends on its target disease, but therapeutic vaccines typically work by activating T-cell and/or B-cell responses to enhance the body's ability to recognize and eliminate disease-associated cells or pathogens.
Approved indications
Common side effects
Key clinical trials
- A Multicenter, Double-blind, Parallel Phase III Study (PHASE3)
- A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GC3110A(Trivalent) CI brief — competitive landscape report
- GC3110A(Trivalent) updates RSS · CI watch RSS
- Green Cross Corporation portfolio CI
Frequently asked questions about GC3110A(Trivalent)
What is GC3110A(Trivalent)?
How does GC3110A(Trivalent) work?
Who makes GC3110A(Trivalent)?
Is GC3110A(Trivalent) also known as anything else?
What drug class is GC3110A(Trivalent) in?
What development phase is GC3110A(Trivalent) in?
Related
- Drug class: All Therapeutic vaccine drugs
- Manufacturer: Green Cross Corporation — full pipeline
- Also known as: GC3110A
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing